| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
558,247 |
493,214 |
$75.16M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
440,043 |
390,235 |
$57.41M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
80,652 |
63,955 |
$32.06M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
149,366 |
131,151 |
$29.40M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
168,222 |
149,761 |
$28.33M |
| 99215 |
Prolong outpt/office vis |
190,774 |
173,688 |
$28.01M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
123,361 |
111,075 |
$21.67M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
523,396 |
373,699 |
$17.75M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
96,271 |
84,047 |
$11.15M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
35,771 |
33,981 |
$10.33M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
83,404 |
65,497 |
$10.06M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
82,693 |
79,986 |
$10.02M |
| J9271 |
Injection, pembrolizumab, 1 mg |
2,320 |
1,749 |
$9.84M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
78,003 |
75,687 |
$8.92M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
197,189 |
74,783 |
$7.70M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
31,453 |
20,164 |
$7.58M |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
3,647 |
3,376 |
$7.10M |
| T1040 |
Medicaid certified community behavioral health clinic services, per diem |
29,380 |
19,553 |
$6.87M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
44,193 |
39,911 |
$6.77M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
9,506 |
9,196 |
$6.58M |
| J2357 |
Injection, omalizumab, 5 mg |
5,504 |
3,539 |
$6.24M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
33,564 |
31,901 |
$6.13M |
| G0378 |
Hospital observation service, per hour |
69,899 |
41,668 |
$5.83M |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
8,406 |
8,130 |
$5.51M |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
9,140 |
8,794 |
$5.30M |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
85,922 |
79,051 |
$5.28M |
| 59025 |
Fetal non-stress test |
17,956 |
12,077 |
$5.25M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
118,190 |
89,324 |
$5.17M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
27,747 |
26,773 |
$5.17M |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
3,215 |
3,029 |
$4.79M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
1,902 |
1,147 |
$4.38M |
| 62323 |
|
9,077 |
8,781 |
$4.35M |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
30,907 |
27,279 |
$4.30M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
46,817 |
45,927 |
$4.27M |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
7,162 |
6,920 |
$4.18M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
13,133 |
12,776 |
$3.99M |
| 99205 |
Prolong outpt/office vis |
28,908 |
27,847 |
$3.86M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
5,531 |
5,378 |
$3.85M |
| 70450 |
Computed tomography, head or brain; without contrast material |
27,148 |
25,156 |
$3.70M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
26,836 |
23,518 |
$3.63M |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
22,576 |
22,035 |
$3.47M |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
23,766 |
20,961 |
$3.43M |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
13,589 |
8,717 |
$3.38M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
4,622 |
4,335 |
$3.38M |
| 87631 |
|
37,155 |
33,419 |
$3.33M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
30,838 |
29,055 |
$3.26M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
118,793 |
113,905 |
$3.12M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
117,650 |
112,831 |
$3.07M |
| 43235 |
|
3,979 |
3,830 |
$3.03M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
25,221 |
23,159 |
$2.96M |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
23,904 |
23,364 |
$2.89M |
| 96415 |
|
7,312 |
5,461 |
$2.76M |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
4,515 |
4,307 |
$2.73M |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
62,706 |
30,379 |
$2.52M |
| 52000 |
|
3,973 |
3,855 |
$2.50M |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
2,121 |
2,089 |
$2.43M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
31,043 |
29,462 |
$2.32M |
| 76830 |
Ultrasound, transvaginal |
23,809 |
23,177 |
$2.31M |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
1,646 |
1,575 |
$2.31M |
| 76801 |
|
19,439 |
17,526 |
$2.25M |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
8,686 |
8,375 |
$2.19M |
| 87481 |
|
52,834 |
47,773 |
$2.19M |
| 93971 |
|
14,655 |
12,905 |
$2.17M |
| 20610 |
|
15,342 |
14,228 |
$2.15M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
25,476 |
25,318 |
$2.15M |
| 31575 |
|
10,980 |
10,601 |
$2.13M |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
23,348 |
22,946 |
$1.99M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
4,238 |
3,498 |
$1.86M |
| 80053 |
Comprehensive metabolic panel |
373,943 |
314,049 |
$1.85M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
404,657 |
318,486 |
$1.83M |
| 76770 |
|
11,805 |
11,474 |
$1.81M |
| 47562 |
|
705 |
665 |
$1.78M |
| 77386 |
|
7,570 |
752 |
$1.75M |
| 97161 |
|
29,523 |
28,525 |
$1.73M |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
9,162 |
8,944 |
$1.60M |
| S9485 |
Crisis intervention mental health services, per diem |
2,864 |
2,234 |
$1.60M |
| 86481 |
|
26,321 |
25,559 |
$1.58M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
60,827 |
57,962 |
$1.58M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13,570 |
13,328 |
$1.56M |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
25,044 |
24,730 |
$1.56M |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
102,892 |
99,210 |
$1.55M |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
3,126 |
2,919 |
$1.55M |
| 76819 |
Fetal biophysical profile; without non-stress testing |
13,389 |
9,022 |
$1.54M |
| 95886 |
|
6,087 |
5,877 |
$1.53M |
| J0178 |
Injection, aflibercept, 1 mg |
1,609 |
1,492 |
$1.52M |
| 11043 |
|
3,437 |
2,002 |
$1.48M |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
37,048 |
36,424 |
$1.48M |
| 97803 |
|
20,789 |
20,409 |
$1.48M |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
21,486 |
16,647 |
$1.48M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
6,878 |
6,515 |
$1.44M |
| 31231 |
|
7,588 |
7,415 |
$1.44M |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
2,960 |
2,865 |
$1.43M |
| 76642 |
|
18,045 |
17,036 |
$1.39M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
33,586 |
28,286 |
$1.37M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
82,907 |
80,575 |
$1.37M |
| 74183 |
|
4,931 |
4,790 |
$1.37M |
| Q5114 |
Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
1,046 |
561 |
$1.36M |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
9,071 |
8,956 |
$1.34M |
| 92552 |
|
19,145 |
18,995 |
$1.33M |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
50,190 |
47,822 |
$1.31M |
| 87511 |
|
49,948 |
47,603 |
$1.30M |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
1,094 |
1,039 |
$1.28M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
12,004 |
11,180 |
$1.28M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
8,402 |
7,768 |
$1.27M |
| 77412 |
|
8,539 |
928 |
$1.23M |
| 19083 |
|
1,777 |
1,671 |
$1.22M |
| 31579 |
|
2,984 |
2,870 |
$1.22M |
| 70496 |
|
4,788 |
4,542 |
$1.22M |
| 76536 |
|
13,631 |
13,348 |
$1.22M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
90,936 |
73,260 |
$1.20M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
15,680 |
15,597 |
$1.19M |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
8,357 |
8,173 |
$1.18M |
| 72141 |
|
5,165 |
5,038 |
$1.17M |
| 95811 |
|
2,266 |
2,159 |
$1.17M |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
19,485 |
17,182 |
$1.17M |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
852 |
830 |
$1.16M |
| 82805 |
|
33,022 |
28,837 |
$1.14M |
| 96402 |
|
4,712 |
4,217 |
$1.12M |
| 83036 |
Hemoglobin; glycosylated (A1C) |
216,352 |
208,756 |
$1.10M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,860 |
5,672 |
$1.09M |
| 71046 |
Radiologic examination, chest; 2 views |
84,715 |
79,021 |
$1.07M |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
11,565 |
11,399 |
$1.07M |
| 99442 |
|
6,137 |
5,870 |
$1.07M |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
4,597 |
4,421 |
$1.06M |
| 84443 |
Thyroid stimulating hormone (TSH) |
111,853 |
108,042 |
$1.05M |
| 98967 |
|
8,834 |
8,160 |
$1.05M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
328 |
301 |
$1.04M |
| 20611 |
|
4,022 |
3,814 |
$1.01M |
| 99443 |
|
5,701 |
5,493 |
$996K |
| Q5115 |
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg |
538 |
313 |
$973K |
| 77300 |
|
2,078 |
1,983 |
$961K |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
1,221 |
1,165 |
$945K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
4,425 |
2,943 |
$934K |
| 93975 |
|
7,400 |
7,061 |
$931K |
| 97802 |
|
14,923 |
14,732 |
$927K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
10,580 |
10,404 |
$927K |
| 97535 |
Self-care/home management training, each 15 minutes |
25,507 |
19,794 |
$926K |
| 92567 |
|
21,677 |
21,278 |
$921K |
| 87486 |
|
35,762 |
33,979 |
$916K |
| 87581 |
|
35,764 |
33,980 |
$915K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
10,050 |
8,978 |
$913K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
2,605 |
2,566 |
$913K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
8,328 |
7,952 |
$875K |
| 87536 |
|
17,287 |
16,636 |
$874K |
| 71250 |
|
11,054 |
10,718 |
$871K |
| 36430 |
|
3,488 |
2,693 |
$853K |
| 86803 |
|
82,730 |
80,459 |
$840K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
153,691 |
149,885 |
$801K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
10,793 |
10,745 |
$800K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
2,040 |
2,001 |
$799K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
4,859 |
3,943 |
$784K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
137,941 |
126,664 |
$760K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
560 |
557 |
$757K |
| 95782 |
|
596 |
593 |
$752K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
9,373 |
9,022 |
$752K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
5,226 |
4,868 |
$743K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
24,944 |
17,324 |
$740K |
| 85027 |
|
175,395 |
160,404 |
$728K |
| 11900 |
|
4,190 |
4,055 |
$711K |
| 70544 |
|
3,409 |
3,254 |
$710K |
| 72197 |
|
2,824 |
2,761 |
$709K |
| 87902 |
|
4,578 |
4,401 |
$709K |
| 93017 |
|
6,827 |
6,622 |
$707K |
| 92015 |
Determination of refractive state |
31,575 |
31,147 |
$703K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
14,797 |
14,115 |
$671K |
| 98966 |
|
5,738 |
5,249 |
$666K |
| 92557 |
|
12,102 |
11,857 |
$659K |
| 86780 |
|
66,883 |
64,921 |
$658K |
| 58300 |
|
2,950 |
2,809 |
$642K |
| 97010 |
|
16,662 |
9,205 |
$641K |
| 93325 |
|
7,107 |
6,923 |
$638K |
| 20550 |
|
4,676 |
4,079 |
$634K |
| 11981 |
|
1,595 |
1,577 |
$632K |
| 76813 |
|
7,383 |
7,204 |
$632K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
155,644 |
131,743 |
$630K |
| 87522 |
Neg quan hep c or qual rna |
21,254 |
20,464 |
$629K |
| ATP14 |
|
68,578 |
57,523 |
$627K |
| 93321 |
|
4,052 |
3,954 |
$617K |
| 10060 |
|
3,285 |
3,132 |
$617K |
| 11056 |
|
5,232 |
5,111 |
$608K |
| 77336 |
|
8,647 |
3,696 |
$608K |
| 92588 |
|
4,385 |
4,321 |
$605K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
89,770 |
78,933 |
$603K |
| 84702 |
|
50,523 |
42,318 |
$602K |
| 73221 |
|
2,793 |
2,683 |
$599K |
| 77080 |
|
11,195 |
11,001 |
$597K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
28,207 |
27,346 |
$589K |
| 92610 |
|
4,026 |
3,786 |
$585K |
| 97162 |
|
11,064 |
10,558 |
$585K |
| 91200 |
|
6,229 |
6,071 |
$578K |
| 87507 |
|
2,143 |
2,044 |
$578K |
| 0001A |
|
16,741 |
14,586 |
$575K |
| 82728 |
|
73,100 |
69,742 |
$572K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
12,941 |
7,798 |
$559K |
| 94060 |
|
6,297 |
6,147 |
$554K |
| 70491 |
|
4,295 |
4,122 |
$545K |
| 93970 |
|
3,104 |
2,914 |
$545K |
| 84484 |
|
70,022 |
52,947 |
$544K |
| 77066 |
Tomosynthesis, mammo |
14,327 |
13,859 |
$542K |
| 96401 |
|
5,893 |
2,628 |
$541K |
| 98968 |
|
4,813 |
4,569 |
$537K |
| 74178 |
|
2,784 |
2,700 |
$534K |
| 96409 |
|
1,376 |
994 |
$531K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
235 |
235 |
$530K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
2,509 |
2,397 |
$514K |
| 70355 |
|
10,584 |
10,202 |
$511K |
| 77065 |
Tomosynthesis, mammo |
12,007 |
11,329 |
$506K |
| J9299 |
Injection, nivolumab, 1 mg |
284 |
206 |
$504K |
| 76882 |
|
5,200 |
5,020 |
$499K |
| 83970 |
|
32,478 |
30,561 |
$497K |
| 90756 |
|
22,723 |
22,347 |
$491K |
| 99385 |
|
4,970 |
4,867 |
$491K |
| 95816 |
|
1,586 |
1,549 |
$481K |
| 20553 |
|
3,100 |
2,946 |
$477K |
| 80061 |
Lipid panel |
153,458 |
149,173 |
$477K |
| 86141 |
|
58,271 |
52,374 |
$472K |
| 99441 |
|
2,828 |
2,600 |
$469K |
| 80050 |
General health panel |
33,513 |
30,898 |
$465K |
| 76818 |
|
3,734 |
2,968 |
$465K |
| 76857 |
|
5,383 |
5,269 |
$464K |
| 11721 |
|
19,181 |
18,728 |
$463K |
| 90715 |
|
23,737 |
23,223 |
$460K |
| 90834 |
Psychotherapy, 45 minutes with patient |
25,667 |
18,527 |
$459K |
| 0011A |
|
20,227 |
18,581 |
$458K |
| 77062 |
|
3,736 |
3,734 |
$453K |
| 62321 |
|
790 |
760 |
$450K |
| 97165 |
|
6,171 |
5,866 |
$450K |
| 84703 |
|
79,696 |
74,387 |
$447K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
206,273 |
176,238 |
$439K |
| 95819 |
|
1,537 |
1,499 |
$433K |
| J7297 |
Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg |
539 |
533 |
$426K |
| 70486 |
|
6,029 |
5,838 |
$423K |
| 76881 |
|
3,947 |
3,728 |
$422K |
| 91322 |
|
6,515 |
6,324 |
$420K |
| 83880 |
|
24,575 |
21,809 |
$418K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
51,271 |
48,679 |
$418K |
| 86850 |
|
72,986 |
64,492 |
$417K |
| 76870 |
|
3,993 |
3,831 |
$415K |
| 83550 |
|
78,203 |
75,421 |
$414K |
| 88142 |
|
32,487 |
31,559 |
$413K |
| 96127 |
|
8,998 |
8,928 |
$402K |
| J1750 |
Injection, iron dextran, 50 mg |
5,389 |
2,849 |
$401K |
| 96416 |
|
2,197 |
1,084 |
$399K |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
1,382 |
1,375 |
$397K |
| 58301 |
|
2,054 |
1,940 |
$374K |
| 64405 |
|
1,115 |
1,082 |
$374K |
| 77061 |
|
2,847 |
2,797 |
$362K |
| 11102 |
|
1,016 |
994 |
$361K |
| 17110 |
|
2,278 |
2,196 |
$358K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
8,435 |
8,273 |
$354K |
| 76820 |
|
7,883 |
4,559 |
$354K |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
7,874 |
7,679 |
$348K |
| 86360 |
|
14,046 |
13,485 |
$343K |
| 82607 |
|
45,929 |
44,375 |
$339K |
| 94726 |
|
7,889 |
7,698 |
$335K |
| 12001 |
|
1,449 |
1,413 |
$331K |
| 81001 |
|
162,633 |
147,192 |
$328K |
| Q3014 |
Telehealth originating site facility fee |
81,028 |
64,844 |
$319K |
| 96367 |
|
5,007 |
3,708 |
$315K |
| 83540 |
|
79,228 |
76,354 |
$311K |
| 44970 |
|
87 |
80 |
$310K |
| 87340 |
|
46,762 |
45,096 |
$309K |
| 77334 |
|
2,088 |
1,656 |
$306K |
| 87641 |
|
17,709 |
16,778 |
$303K |
| 92083 |
|
14,920 |
14,596 |
$301K |
| 83735 |
|
86,913 |
62,036 |
$299K |
| 83605 |
|
39,519 |
32,393 |
$297K |
| 51741 |
|
4,274 |
4,180 |
$288K |
| 86359 |
|
14,876 |
14,227 |
$285K |
| 90651 |
|
6,047 |
5,922 |
$285K |
| J9306 |
Injection, pertuzumab, 1 mg |
251 |
153 |
$285K |
| 83690 |
|
59,631 |
54,071 |
$284K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
250 |
227 |
$278K |
| 94010 |
|
5,405 |
5,255 |
$278K |
| 58100 |
|
1,439 |
1,370 |
$277K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
31,474 |
29,357 |
$276K |
| 88307 |
|
5,681 |
4,852 |
$276K |
| 82330 |
|
33,831 |
29,663 |
$275K |
| 86706 |
|
42,083 |
40,523 |
$273K |
| 97166 |
|
4,032 |
3,676 |
$271K |
| 92134 |
|
24,422 |
23,108 |
$270K |
| 0002A |
|
7,339 |
6,769 |
$267K |
| 87563 |
|
12,586 |
12,158 |
$266K |
| 57454 |
|
840 |
829 |
$263K |
| 94729 |
|
7,443 |
7,270 |
$257K |
| 72100 |
|
13,653 |
13,213 |
$255K |
| 11055 |
|
1,925 |
1,889 |
$253K |
| 71271 |
|
5,808 |
5,676 |
$252K |
| 73630 |
|
22,636 |
19,347 |
$249K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
64,382 |
49,700 |
$247K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,941 |
2,008 |
$245K |
| 11982 |
|
1,187 |
1,163 |
$244K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
72,155 |
59,206 |
$242K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
2,407 |
2,370 |
$241K |
| 70547 |
|
1,741 |
1,643 |
$239K |
| 0064A |
|
9,962 |
9,671 |
$234K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
9,848 |
9,563 |
$230K |
| 73030 |
|
17,665 |
16,210 |
$229K |
| 64493 |
|
704 |
671 |
$229K |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
138 |
96 |
$226K |
| 99386 |
|
2,766 |
2,718 |
$224K |
| 97116 |
|
9,076 |
5,748 |
$224K |
| 90677 |
|
8,637 |
8,533 |
$224K |
| 85610 |
|
98,854 |
75,884 |
$223K |
| 86003 |
|
5,435 |
5,287 |
$221K |
| 73564 |
|
15,657 |
13,721 |
$220K |
| J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg |
277 |
152 |
$218K |
| 90791 |
Psychiatric diagnostic evaluation |
6,978 |
6,658 |
$217K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
73,670 |
59,817 |
$216K |
| 77280 |
|
2,145 |
2,015 |
$214K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
74,268 |
61,286 |
$213K |
| 0012A |
|
8,285 |
7,652 |
$212K |
| 82746 |
|
29,825 |
28,759 |
$212K |
| 51728 |
|
1,008 |
995 |
$212K |
| 0004A |
|
6,650 |
6,454 |
$211K |
| 12011 |
|
889 |
874 |
$209K |
| 78999 |
|
3,890 |
3,688 |
$208K |
| ATP08 |
|
29,740 |
23,967 |
$208K |
| 90480 |
|
7,911 |
7,717 |
$206K |
| 81329 |
|
2,070 |
2,008 |
$205K |
| J2704 |
Injection, propofol, 10 mg |
71,675 |
63,797 |
$205K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
39,276 |
35,408 |
$203K |
| 76942 |
|
4,026 |
3,817 |
$200K |
| 77014 |
|
22,160 |
2,521 |
$199K |
| 82784 |
|
20,274 |
18,434 |
$198K |
| G0382 |
Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
5,021 |
4,741 |
$197K |
| 84403 |
|
12,873 |
12,412 |
$197K |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
450 |
409 |
$195K |
| 90688 |
|
12,502 |
12,303 |
$194K |
| 88342 |
|
8,257 |
7,664 |
$194K |
| 92579 |
|
4,724 |
4,665 |
$194K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
1,925 |
1,392 |
$194K |
| 90837 |
Psychotherapy, 53 minutes with patient |
8,157 |
5,051 |
$193K |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
103 |
101 |
$193K |
| 84439 |
|
35,420 |
33,473 |
$191K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,356 |
3,276 |
$190K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
11,791 |
10,953 |
$189K |
| 86704 |
|
27,188 |
26,022 |
$189K |
| J1437 |
Injection, ferric derisomaltose, 10 mg |
220 |
219 |
$183K |
| 70498 |
|
4,124 |
3,902 |
$182K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
16,499 |
15,815 |
$182K |
| 85730 |
|
37,138 |
33,802 |
$181K |
| J0574 |
Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine |
6,501 |
3,174 |
$180K |
| 83021 |
|
12,920 |
11,986 |
$179K |
| 87480 |
|
10,294 |
9,812 |
$178K |
| 86900 |
|
73,504 |
64,331 |
$177K |
| 87510 |
|
10,300 |
9,817 |
$177K |
| 87660 |
|
10,298 |
9,816 |
$176K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
58,492 |
53,891 |
$176K |
| 74174 |
|
1,544 |
1,471 |
$175K |
| 73610 |
|
17,696 |
15,485 |
$174K |
| 69210 |
|
5,021 |
4,863 |
$173K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,151 |
4,043 |
$172K |
| 87077 |
|
29,410 |
27,492 |
$172K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
17,307 |
6,368 |
$170K |
| 72158 |
|
939 |
914 |
$170K |
| J0897 |
Injection, denosumab, 1 mg |
328 |
305 |
$169K |
| 90746 |
|
8,262 |
8,080 |
$169K |
| 73130 |
|
19,089 |
15,370 |
$168K |
| D7140 |
Extraction, erupted tooth or exposed root |
706 |
374 |
$168K |
| 84153 |
|
22,263 |
20,600 |
$167K |
| 87430 |
|
13,811 |
13,386 |
$165K |
| 93923 |
|
2,210 |
2,133 |
$164K |
| 10005 |
|
766 |
734 |
$164K |
| 86901 |
|
73,877 |
64,623 |
$163K |
| 86480 |
|
3,817 |
3,675 |
$161K |
| 81229 |
|
188 |
173 |
$161K |
| 82274 |
|
19,638 |
19,308 |
$161K |
| 64615 |
|
607 |
587 |
$160K |
| 46607 |
|
296 |
294 |
$160K |
| 86762 |
|
15,455 |
15,002 |
$157K |
| 86787 |
|
17,007 |
16,483 |
$157K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
4,123 |
3,541 |
$155K |
| 92504 |
|
6,244 |
5,995 |
$155K |
| J3490 |
Unclassified drugs |
9,272 |
7,568 |
$152K |
| 78431 |
|
138 |
130 |
$151K |
| 84425 |
|
14,526 |
14,161 |
$148K |
| 87186 |
|
24,997 |
23,384 |
$148K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
29,250 |
23,764 |
$147K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
4,994 |
4,560 |
$147K |
| 90832 |
Psychotherapy, 30 minutes with patient |
10,960 |
9,318 |
$147K |
| 52356 |
|
45 |
42 |
$146K |
| 82948 |
|
39,883 |
30,227 |
$146K |
| D7230 |
|
290 |
257 |
$145K |
| Q0139 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) |
624 |
465 |
$144K |
| J9312 |
Injection, rituximab, 10 mg |
121 |
76 |
$144K |
| 88112 |
|
5,795 |
5,506 |
$142K |
| 73560 |
|
13,527 |
12,090 |
$141K |
| 90674 |
|
7,064 |
6,884 |
$139K |
| ATP15 |
|
16,328 |
13,275 |
$138K |
| 87517 |
|
5,718 |
5,504 |
$137K |
| 87040 |
|
12,271 |
9,789 |
$136K |
| 87081 |
|
23,942 |
23,300 |
$135K |
| 80069 |
|
42,682 |
35,421 |
$134K |
| 92553 |
|
4,099 |
4,027 |
$134K |
| 77295 |
|
331 |
315 |
$134K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
2,543 |
2,287 |
$134K |
| 74230 |
|
912 |
890 |
$133K |
| 36561 |
|
170 |
162 |
$132K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
21,620 |
16,736 |
$131K |
| J1644 |
Injection, heparin sodium, per 1000 units |
29,775 |
15,790 |
$130K |
| 92133 |
|
12,914 |
12,647 |
$130K |
| 12002 |
|
595 |
580 |
$129K |
| J1815 |
Injection, insulin, per 5 units |
35,332 |
12,216 |
$127K |
| J9041 |
Injection, bortezomib, 0.1 mg |
319 |
65 |
$127K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
8,489 |
6,089 |
$126K |
| 71045 |
Radiologic examination, chest; single view |
30,789 |
27,783 |
$125K |
| 82105 |
|
12,326 |
11,781 |
$124K |
| G0270 |
Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes |
8,262 |
7,937 |
$123K |
| 86708 |
|
14,736 |
14,280 |
$121K |
| 72040 |
|
6,120 |
5,945 |
$119K |
| 82947 |
|
60,707 |
42,634 |
$118K |
| G0008 |
Administration of influenza virus vaccine |
21,298 |
20,605 |
$117K |
| D7240 |
Removal of impacted tooth - completely bony |
269 |
213 |
$116K |
| 82670 |
|
6,527 |
6,202 |
$116K |
| 93798 |
|
2,780 |
711 |
$115K |
| 70543 |
|
371 |
361 |
$114K |
| 92020 |
|
1,569 |
1,528 |
$114K |
| 83001 |
|
9,432 |
9,111 |
$113K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
13,309 |
8,343 |
$112K |
| 82043 |
|
43,052 |
41,661 |
$111K |
| 77290 |
|
675 |
652 |
$110K |
| 72156 |
|
459 |
446 |
$110K |
| 95115 |
|
3,885 |
1,465 |
$110K |
| 19318 |
|
39 |
38 |
$109K |
| 84146 |
|
9,158 |
8,849 |
$109K |
| 78803 |
|
462 |
417 |
$109K |
| 99218 |
|
977 |
429 |
$108K |
| 81025 |
|
20,671 |
18,937 |
$106K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,402 |
2,160 |
$106K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
55,091 |
53,732 |
$105K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
56 |
56 |
$104K |
| 93880 |
|
942 |
897 |
$104K |
| 87428 |
|
1,777 |
1,736 |
$104K |
| 0124A |
|
3,864 |
3,751 |
$104K |
| 95911 |
|
1,439 |
1,419 |
$102K |
| 11104 |
|
276 |
270 |
$102K |
| 11100 |
|
425 |
412 |
$101K |
| 73502 |
|
10,344 |
9,835 |
$101K |
| 95912 |
|
1,113 |
1,105 |
$100K |
| 99201 |
|
840 |
821 |
$100K |
| 82951 |
|
8,831 |
8,130 |
$99K |
| 10061 |
|
565 |
541 |
$97K |
| 88341 |
|
5,234 |
4,674 |
$97K |
| 84480 |
|
12,286 |
11,338 |
$96K |
| 73110 |
|
9,801 |
8,646 |
$96K |
| 97804 |
|
989 |
985 |
$95K |
| 95028 |
|
477 |
474 |
$94K |
| 84270 |
|
6,281 |
6,127 |
$92K |
| 72110 |
|
7,417 |
7,231 |
$92K |
| 36415 |
Collection of venous blood by venipuncture |
143,329 |
126,249 |
$91K |
| 20605 |
|
707 |
657 |
$91K |
| 86334 |
|
10,912 |
9,572 |
$90K |
| 76775 |
|
743 |
729 |
$89K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
2,861 |
2,761 |
$89K |
| 86920 |
|
877 |
776 |
$88K |
| 93351 |
|
3,054 |
2,988 |
$88K |
| 90662 |
|
11,352 |
10,856 |
$87K |
| 82962 |
|
55,476 |
36,839 |
$87K |
| 80074 |
|
2,761 |
2,622 |
$86K |
| 97810 |
|
1,246 |
648 |
$86K |
| 76937 |
|
2,107 |
1,974 |
$85K |
| 20526 |
|
766 |
715 |
$85K |
| 93308 |
|
508 |
486 |
$84K |
| 85652 |
|
50,880 |
46,309 |
$83K |
| 84445 |
|
2,938 |
2,854 |
$83K |
| ATP17 |
|
10,589 |
9,635 |
$83K |
| 94618 |
|
811 |
750 |
$83K |
| 95913 |
|
912 |
896 |
$82K |
| 66761 |
|
123 |
110 |
$82K |
| 86160 |
|
6,981 |
6,627 |
$82K |
| 0134A |
|
4,400 |
4,236 |
$81K |
| 83013 |
|
1,680 |
1,666 |
$79K |
| 88173 |
|
2,809 |
2,544 |
$77K |
| 78492 |
|
59 |
58 |
$77K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
1,428 |
585 |
$77K |
| 80076 |
|
21,101 |
20,170 |
$76K |
| 0071A |
|
1,914 |
1,911 |
$76K |
| 86038 |
|
11,381 |
10,903 |
$76K |
| 0072A |
|
1,706 |
1,705 |
$76K |
| 19499 |
|
95 |
95 |
$75K |
| J0791 |
Injection, crizanlizumab-tmca, 5 mg |
122 |
113 |
$75K |
| 83002 |
|
5,781 |
5,622 |
$75K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
29,007 |
24,218 |
$74K |
| 87150 |
|
2,388 |
2,351 |
$74K |
| 0031A |
|
2,651 |
2,457 |
$74K |
| 85379 |
|
10,842 |
9,909 |
$74K |
| 82570 |
|
30,673 |
26,152 |
$74K |
| 82378 |
|
10,012 |
7,353 |
$74K |
| 92136 |
|
2,641 |
2,546 |
$73K |
| 86765 |
|
9,133 |
8,830 |
$72K |
| J3489 |
Injection, zoledronic acid, 1 mg |
2,866 |
2,705 |
$72K |
| 99381 |
|
465 |
460 |
$71K |
| 51784 |
|
622 |
611 |
$71K |
| 87799 |
|
5,157 |
4,339 |
$71K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
2,178 |
1,729 |
$70K |
| 86735 |
|
8,757 |
8,491 |
$70K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
27,924 |
16,782 |
$69K |
| 96411 |
|
3,460 |
2,186 |
$69K |
| H2016 |
Comprehensive community support services, per diem |
2,481 |
101 |
$69K |
| 86923 |
|
3,089 |
2,506 |
$68K |
| 72052 |
|
3,360 |
3,254 |
$68K |
| 90732 |
|
4,663 |
4,537 |
$67K |
| 92611 |
|
851 |
829 |
$67K |
| 87070 |
|
11,512 |
10,483 |
$67K |
| 93296 |
|
2,322 |
2,261 |
$66K |
| 92526 |
|
800 |
641 |
$65K |
| 82248 |
|
35,121 |
29,738 |
$64K |
| 81003 |
|
42,738 |
40,187 |
$64K |
| 82565 |
|
30,605 |
28,744 |
$64K |
| 83525 |
|
8,692 |
8,502 |
$62K |
| 95806 |
|
242 |
241 |
$62K |
| 77387 |
|
2,908 |
429 |
$62K |
| 96376 |
|
23,077 |
14,309 |
$61K |
| 92558 |
|
3,402 |
3,350 |
$61K |
| 83883 |
|
9,950 |
5,735 |
$60K |
| 87529 |
|
2,390 |
2,284 |
$60K |
| 86235 |
|
3,536 |
3,330 |
$60K |
| J3471 |
Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) |
789 |
742 |
$60K |
| 88185 |
|
454 |
416 |
$59K |
| 87535 |
|
2,442 |
2,361 |
$58K |
| 74240 |
|
348 |
346 |
$58K |
| 87338 |
|
5,987 |
5,900 |
$58K |
| 20551 |
|
422 |
392 |
$58K |
| ATP10 |
|
8,720 |
6,513 |
$57K |
| 95117 |
|
1,734 |
886 |
$57K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
554 |
520 |
$57K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
4,515 |
4,152 |
$57K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
22,035 |
17,710 |
$57K |
| 76604 |
|
796 |
767 |
$57K |
| 82785 |
|
5,051 |
4,926 |
$57K |
| 88304 |
|
11,282 |
10,612 |
$56K |
| 90694 |
|
4,574 |
4,443 |
$55K |
| 87538 |
|
2,260 |
2,184 |
$54K |
| 51785 |
|
504 |
496 |
$54K |
| 84156 |
|
31,980 |
27,227 |
$53K |
| J0485 |
Injection, belatacept, 1 mg |
119 |
61 |
$53K |
| 64483 |
|
94 |
87 |
$53K |
| 73562 |
|
7,501 |
6,034 |
$53K |
| G0271 |
Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes |
1,872 |
1,826 |
$53K |
| 87640 |
|
3,890 |
3,700 |
$52K |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
347 |
165 |
$52K |
| 93280 |
|
1,842 |
1,775 |
$52K |
| 99397 |
|
1,018 |
983 |
$52K |
| 64721 |
|
91 |
90 |
$51K |
| 84145 |
|
3,408 |
2,880 |
$51K |
| 87088 |
|
9,632 |
9,129 |
$51K |
| 84165 |
|
11,588 |
10,282 |
$51K |
| 11720 |
|
1,629 |
1,601 |
$50K |
| 84100 |
|
37,071 |
29,305 |
$50K |
| 73140 |
|
4,291 |
4,024 |
$49K |
| 77072 |
|
970 |
968 |
$48K |
| 80177 |
|
5,465 |
4,989 |
$48K |
| 90734 |
|
2,200 |
2,149 |
$48K |
| 73590 |
|
7,129 |
6,419 |
$47K |
| 99495 |
|
997 |
977 |
$47K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
56 |
52 |
$46K |
| 58558 |
|
76 |
65 |
$46K |
| 70480 |
|
578 |
561 |
$46K |
| 77049 |
|
264 |
258 |
$45K |
| ATP03 |
|
20,006 |
17,666 |
$45K |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
12,041 |
7,961 |
$44K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
326 |
320 |
$44K |
| 92555 |
|
4,676 |
4,596 |
$43K |
| 84163 |
|
3,116 |
3,053 |
$43K |
| 83516 |
|
4,516 |
4,365 |
$43K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
13,069 |
11,657 |
$42K |
| J9035 |
Injection, bevacizumab, 10 mg |
69 |
48 |
$42K |
| 90632 |
|
1,770 |
1,736 |
$42K |
| 99496 |
|
729 |
711 |
$41K |
| 81596 |
|
841 |
827 |
$41K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
22,152 |
20,410 |
$41K |
| 90670 |
|
9,863 |
9,714 |
$40K |
| 92002 |
|
610 |
595 |
$40K |
| 86800 |
|
5,062 |
4,870 |
$40K |
| 58661 |
|
82 |
44 |
$40K |
| 90658 |
|
2,215 |
2,109 |
$39K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
2,419 |
1,369 |
$39K |
| 90739 |
|
2,049 |
2,014 |
$39K |
| G0381 |
Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
1,239 |
1,190 |
$39K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
23,910 |
22,826 |
$38K |
| 86376 |
|
4,340 |
4,217 |
$38K |
| 97164 |
|
865 |
820 |
$38K |
| 73080 |
|
4,723 |
4,338 |
$37K |
| 86255 |
|
5,244 |
4,966 |
$37K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
11,810 |
8,320 |
$37K |
| 82533 |
|
3,903 |
3,508 |
$37K |
| J9310 |
Injection, rituximab, 100 mg |
58 |
38 |
$37K |
| 49650 |
|
32 |
29 |
$36K |
| 82550 |
|
19,412 |
17,451 |
$36K |
| 96111 |
|
426 |
379 |
$36K |
| 90620 |
|
194 |
194 |
$36K |
| 74018 |
|
2,882 |
2,581 |
$36K |
| 77073 |
|
6,381 |
6,147 |
$36K |
| 85045 |
|
14,915 |
12,868 |
$36K |
| 82088 |
|
1,936 |
1,852 |
$36K |
| 80164 |
|
4,344 |
3,894 |
$35K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
7,669 |
6,779 |
$35K |
| 80197 |
|
9,644 |
6,673 |
$35K |
| 83519 |
|
3,008 |
2,847 |
$34K |
| 0003A |
|
1,129 |
1,096 |
$34K |
| 20552 |
|
208 |
200 |
$34K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,622 |
2,572 |
$34K |
| 87205 |
|
12,028 |
10,962 |
$34K |
| ATP16 |
|
3,946 |
3,150 |
$34K |
| 97811 |
|
1,038 |
538 |
$33K |
| 83521 |
|
5,963 |
5,247 |
$33K |
| 92587 |
|
159 |
158 |
$33K |
| 92582 |
|
1,154 |
1,142 |
$33K |
| 83921 |
|
3,853 |
3,716 |
$32K |
| 92250 |
|
3,937 |
3,625 |
$32K |
| 30520 |
|
26 |
25 |
$32K |
| 96112 |
|
2,251 |
2,175 |
$32K |
| 77301 |
|
72 |
70 |
$32K |
| 96910 |
|
763 |
131 |
$32K |
| 99383 |
|
291 |
290 |
$32K |
| 82525 |
|
5,288 |
5,139 |
$31K |
| 84630 |
|
5,578 |
5,419 |
$31K |
| 0013A |
|
1,578 |
1,532 |
$31K |
| 78306 |
|
244 |
237 |
$30K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
71 |
49 |
$30K |
| 73700 |
|
434 |
416 |
$30K |
| 72131 |
|
732 |
711 |
$30K |
| ATP11 |
|
4,448 |
4,128 |
$30K |
| 92025 |
|
1,538 |
1,483 |
$30K |
| 96417 |
|
6,989 |
4,389 |
$29K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
13,777 |
6,164 |
$29K |
| J2060 |
Injection, lorazepam, 2 mg |
12,066 |
9,258 |
$29K |
| 82077 |
|
5,627 |
5,320 |
$29K |
| 67228 |
|
75 |
69 |
$29K |
| 84436 |
|
7,259 |
6,740 |
$29K |
| 95910 |
|
333 |
325 |
$28K |
| 11730 |
|
356 |
348 |
$28K |
| 86870 |
|
386 |
364 |
$28K |
| 86677 |
|
3,193 |
3,095 |
$28K |
| 74019 |
|
2,328 |
2,237 |
$27K |
| 84134 |
|
4,705 |
4,490 |
$27K |
| 55700 |
|
79 |
75 |
$27K |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
11,869 |
11,117 |
$27K |
| 82627 |
|
1,726 |
1,687 |
$26K |
| 72070 |
|
1,747 |
1,678 |
$26K |
| 84460 |
|
19,964 |
19,199 |
$26K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
3,658 |
3,438 |
$26K |
| 86753 |
|
2,920 |
2,820 |
$26K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
2,530 |
2,297 |
$26K |
| 73090 |
|
4,747 |
4,386 |
$26K |
| 0054A |
|
771 |
762 |
$26K |
| 83721 |
|
6,108 |
5,913 |
$26K |
| 99382 |
|
209 |
208 |
$26K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
14,156 |
8,535 |
$26K |
| 84450 |
|
18,778 |
18,054 |
$25K |
| 73552 |
|
3,104 |
2,822 |
$25K |
| 84432 |
|
3,511 |
3,361 |
$25K |
| 64450 |
|
173 |
169 |
$25K |
| 90686 |
|
18,523 |
18,341 |
$25K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
935 |
804 |
$25K |
| 84166 |
|
3,319 |
3,036 |
$25K |
| 90653 |
|
1,742 |
1,727 |
$25K |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
297 |
103 |
$25K |
| 86902 |
|
489 |
430 |
$25K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
23,592 |
21,194 |
$25K |
| 87075 |
|
4,051 |
3,684 |
$24K |
| 83615 |
|
15,883 |
13,084 |
$24K |
| J1630 |
Injection, haloperidol, up to 5 mg |
10,795 |
8,640 |
$24K |
| 29125 |
|
272 |
253 |
$24K |
| 72170 |
|
2,400 |
2,227 |
$23K |
| 84305 |
|
1,613 |
1,584 |
$23K |
| 86617 |
|
1,559 |
1,365 |
$23K |
| 76000 |
|
469 |
422 |
$23K |
| 25600 |
|
41 |
40 |
$23K |
| 92060 |
|
1,282 |
1,251 |
$23K |
| 87901 |
|
141 |
139 |
$22K |
| J7999 |
Compounded drug, not otherwise classified |
3,109 |
2,963 |
$22K |
| 46600 |
|
2,913 |
2,854 |
$22K |
| 86200 |
|
3,625 |
3,449 |
$22K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
2,866 |
2,751 |
$22K |
| 96040 |
|
3,012 |
2,817 |
$22K |
| J3411 |
Injection, thiamine hcl, 100 mg |
4,083 |
3,046 |
$22K |
| J0248 |
Injection, remdesivir, 1 mg |
86 |
26 |
$22K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
282 |
257 |
$21K |
| 86580 |
|
2,542 |
2,429 |
$21K |
| 70487 |
|
179 |
174 |
$21K |
| 84550 |
|
14,113 |
12,186 |
$21K |
| G0009 |
Administration of pneumococcal vaccine |
4,232 |
4,140 |
$21K |
| 99384 |
|
155 |
155 |
$21K |
| 83014 |
|
4,039 |
3,978 |
$21K |
| H2015 |
Comprehensive community support services, per 15 minutes |
1,153 |
935 |
$21K |
| 80179 |
|
3,255 |
3,041 |
$21K |
| 86147 |
|
1,561 |
1,483 |
$21K |
| 86316 |
|
3,247 |
2,462 |
$20K |
| 77001 |
|
541 |
515 |
$20K |
| 96368 |
|
3,801 |
2,404 |
$20K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
8,596 |
6,220 |
$20K |
| 76998 |
|
310 |
305 |
$20K |
| 0154A |
|
432 |
432 |
$20K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
271 |
171 |
$20K |
| 84244 |
|
1,993 |
1,922 |
$20K |
| V2632 |
Posterior chamber intraocular lens |
1,989 |
1,900 |
$20K |
| 86039 |
|
3,239 |
3,101 |
$20K |
| 82040 |
|
11,223 |
10,813 |
$20K |
| 73060 |
|
3,635 |
3,341 |
$19K |
| 82150 |
|
4,378 |
4,199 |
$19K |
| 87184 |
|
4,209 |
3,899 |
$19K |
| 86364 |
|
3,565 |
3,506 |
$18K |
| Q5126 |
Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg |
92 |
73 |
$18K |
| 83520 |
|
1,976 |
1,918 |
$18K |
| ATP07 |
|
2,536 |
2,331 |
$18K |
| 73100 |
|
2,222 |
1,876 |
$18K |
| 84479 |
|
5,082 |
4,935 |
$17K |
| 64612 |
|
99 |
98 |
$17K |
| 86665 |
|
857 |
768 |
$17K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
28 |
25 |
$17K |
| G0399 |
Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation |
230 |
223 |
$17K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
4,479 |
4,127 |
$17K |
| 83789 |
|
1,070 |
1,025 |
$16K |
| 88313 |
|
1,332 |
1,145 |
$16K |
| 87102 |
|
3,092 |
2,809 |
$16K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
5,851 |
5,287 |
$16K |
| 86431 |
|
5,677 |
5,438 |
$16K |
| 0081A |
|
533 |
531 |
$16K |
| 87015 |
|
3,841 |
3,136 |
$16K |
| 72082 |
|
727 |
706 |
$16K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
792 |
693 |
$16K |
| 86592 |
|
5,641 |
5,418 |
$16K |
| J2785 |
Injection, regadenoson, 0.1 mg |
3,201 |
3,061 |
$16K |
| 19081 |
|
13 |
12 |
$16K |
| J0572 |
Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine |
412 |
220 |
$16K |
| ATP09 |
|
2,137 |
1,802 |
$15K |
| 0052A |
|
366 |
364 |
$15K |
| 86146 |
|
1,157 |
1,092 |
$15K |
| 86696 |
|
1,289 |
1,190 |
$15K |
| J7300 |
Intrauterine copper contraceptive (paragard) |
53 |
53 |
$15K |
| 93304 |
|
54 |
53 |
$15K |
| J0401 |
Injection, aripiprazole (abilify maintena), 1 mg |
12 |
12 |
$15K |
| 86335 |
|
1,636 |
1,493 |
$15K |
| 87632 |
|
106 |
106 |
$15K |
| 87906 |
|
186 |
180 |
$15K |
| 82024 |
|
720 |
685 |
$14K |
| 80143 |
|
2,767 |
2,610 |
$14K |
| 86682 |
|
1,904 |
1,792 |
$14K |
| 86705 |
|
2,069 |
2,006 |
$14K |
| 29581 |
|
113 |
54 |
$14K |
| 82553 |
|
2,608 |
2,352 |
$14K |
| 88184 |
|
635 |
559 |
$14K |
| 82960 |
|
2,812 |
2,743 |
$13K |
| 92524 |
|
197 |
194 |
$13K |
| ATP02 |
|
3,398 |
2,970 |
$13K |
| ATP18 |
|
1,698 |
1,515 |
$13K |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
329 |
260 |
$13K |
| 65855 |
|
48 |
41 |
$13K |
| 0051A |
|
322 |
320 |
$13K |
| 87900 |
|
141 |
139 |
$13K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
169 |
155 |
$13K |
| 76512 |
|
214 |
190 |
$13K |
| 87116 |
|
2,298 |
1,626 |
$13K |
| 84132 |
|
12,832 |
11,502 |
$13K |
| 73523 |
|
948 |
919 |
$13K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
6,460 |
5,993 |
$13K |
| 93282 |
|
466 |
454 |
$13K |
| 96523 |
|
514 |
406 |
$13K |
| 76885 |
|
92 |
92 |
$13K |
| 84590 |
|
2,271 |
2,212 |
$13K |
| 51600 |
|
96 |
94 |
$13K |
| 85384 |
|
2,553 |
2,033 |
$13K |
| 72146 |
|
129 |
126 |
$12K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
45 |
25 |
$12K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
2,523 |
2,451 |
$12K |
| 89051 |
|
4,012 |
3,580 |
$12K |
| 85018 |
|
8,487 |
7,701 |
$12K |
| 15852 |
|
44 |
25 |
$12K |
| 76514 |
|
507 |
486 |
$12K |
| 99412 |
|
348 |
217 |
$12K |
| ATP04 |
|
2,141 |
1,765 |
$12K |
| 90707 |
|
4,283 |
4,219 |
$12K |
| 86021 |
|
1,464 |
1,363 |
$12K |
| 82977 |
|
5,580 |
5,360 |
$11K |
| G0383 |
Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
352 |
342 |
$11K |
| 72114 |
|
1,270 |
1,248 |
$11K |
| 83010 |
|
1,871 |
1,663 |
$11K |
| A9581 |
Injection, gadoxetate disodium, 1 ml |
628 |
624 |
$11K |
| 84295 |
|
11,791 |
10,642 |
$11K |
| 81002 |
|
5,417 |
4,960 |
$11K |
| 91321 |
|
1,106 |
1,100 |
$11K |
| 97597 |
|
85 |
68 |
$11K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
17 |
14 |
$10K |
| 77338 |
|
72 |
70 |
$10K |
| 83498 |
|
513 |
507 |
$10K |
| Q5123 |
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg |
68 |
25 |
$10K |
| 81401 |
|
129 |
125 |
$10K |
| 64494 |
|
361 |
345 |
$10K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
2,160 |
2,072 |
$10K |
| 86709 |
|
1,653 |
1,567 |
$10K |
| 86645 |
|
934 |
864 |
$10K |
| 0082A |
|
230 |
230 |
$9K |
| 91301 |
|
21,688 |
19,255 |
$9K |
| 51798 |
|
4,255 |
4,133 |
$9K |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
972 |
909 |
$9K |
| 82610 |
|
1,145 |
1,100 |
$9K |
| ATP05 |
|
1,411 |
1,180 |
$9K |
| 86301 |
|
1,159 |
937 |
$9K |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
3,309 |
2,672 |
$9K |
| G0010 |
Administration of hepatitis b vaccine |
1,851 |
1,796 |
$9K |
| 85705 |
|
1,732 |
1,646 |
$9K |
| 82397 |
|
977 |
931 |
$9K |
| 82435 |
|
10,994 |
9,884 |
$9K |
| 90656 |
|
2,042 |
2,039 |
$9K |
| 20600 |
|
54 |
49 |
$8K |
| 86644 |
|
934 |
864 |
$8K |
| 74241 |
|
28 |
28 |
$8K |
| J7626 |
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg |
1,325 |
641 |
$8K |
| 17000 |
|
153 |
147 |
$8K |
| 72157 |
|
89 |
88 |
$8K |
| Q0166 |
Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
12,886 |
7,043 |
$8K |
| 93299 |
|
290 |
281 |
$8K |
| 84466 |
|
1,436 |
1,395 |
$8K |
| 87493 |
|
410 |
398 |
$8K |
| 86695 |
|
945 |
877 |
$8K |
| J9045 |
Injection, carboplatin, 50 mg |
1,828 |
1,113 |
$8K |
| C8930 |
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision |
64 |
62 |
$8K |
| 90691 |
|
923 |
916 |
$8K |
| 81455 |
|
14 |
14 |
$8K |
| 86664 |
|
830 |
780 |
$8K |
| 83993 |
|
682 |
649 |
$8K |
| 86304 |
|
1,126 |
916 |
$8K |
| 80230 |
|
350 |
331 |
$8K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
86 |
70 |
$7K |
| 65426 |
|
12 |
12 |
$7K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
20,444 |
10,913 |
$7K |
| 99173 |
|
461 |
460 |
$7K |
| 72190 |
|
595 |
567 |
$7K |
| 82310 |
|
4,974 |
4,681 |
$7K |
| J9171 |
Injection, docetaxel, 1 mg |
69 |
51 |
$7K |
| 76821 |
|
766 |
711 |
$7K |
| 82247 |
|
3,932 |
3,224 |
$7K |
| 87899 |
|
755 |
710 |
$7K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
3,739 |
1,904 |
$7K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
1,738 |
1,571 |
$7K |
| 90714 |
|
562 |
553 |
$7K |
| 82985 |
|
1,053 |
1,025 |
$7K |
| 10022 |
|
78 |
77 |
$7K |
| 95714 |
|
35 |
27 |
$7K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
9,881 |
9,104 |
$7K |
| 85613 |
|
1,234 |
1,167 |
$6K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
1,039 |
996 |
$6K |
| 82652 |
|
370 |
367 |
$6K |
| 86336 |
|
447 |
431 |
$6K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
9,712 |
9,019 |
$6K |
| A9595 |
Piflufolastat f-18, diagnostic, 1 millicurie |
16 |
14 |
$6K |
| 86663 |
|
777 |
736 |
$6K |
| 73070 |
|
813 |
716 |
$6K |
| 93225 |
|
175 |
165 |
$6K |
| 86355 |
|
262 |
243 |
$6K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
5,043 |
1,597 |
$6K |
| 97022 |
|
116 |
51 |
$6K |
| 90661 |
|
497 |
470 |
$6K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
3,554 |
3,412 |
$6K |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
89 |
77 |
$6K |
| 87154 |
|
34 |
33 |
$6K |
| 84520 |
|
4,667 |
4,323 |
$6K |
| 86357 |
|
244 |
227 |
$6K |
| 77003 |
|
87 |
84 |
$6K |
| 0034A |
|
362 |
344 |
$6K |
| 83655 |
|
642 |
607 |
$6K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
1,064 |
982 |
$6K |
| C1769 |
Guide wire |
2,197 |
1,986 |
$6K |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
15,395 |
10,433 |
$6K |
| 42826 |
|
12 |
12 |
$6K |
| G0127 |
Trimming of dystrophic nails, any number |
465 |
454 |
$6K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,685 |
2,292 |
$5K |
| 95716 |
|
14 |
13 |
$5K |
| 90474 |
|
8,541 |
8,443 |
$5K |
| 84681 |
|
519 |
502 |
$5K |
| 90717 |
|
134 |
134 |
$5K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
202 |
199 |
$5K |
| 82677 |
|
266 |
255 |
$5K |
| J9206 |
Injection, irinotecan, 20 mg |
106 |
61 |
$5K |
| 51701 |
|
723 |
711 |
$5K |
| 83835 |
|
607 |
561 |
$5K |
| 88300 |
|
1,114 |
1,093 |
$5K |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
193 |
167 |
$5K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
5,209 |
4,722 |
$5K |
| 57456 |
|
12 |
12 |
$5K |
| 25605 |
|
13 |
12 |
$5K |
| 74220 |
|
139 |
133 |
$5K |
| 84300 |
|
1,626 |
1,364 |
$5K |
| J0135 |
Injection, adalimumab, 20 mg |
333 |
197 |
$5K |
| 92523 |
|
29 |
29 |
$4K |
| 72072 |
|
189 |
186 |
$4K |
| 82103 |
|
730 |
709 |
$4K |
| J0290 |
Injection, ampicillin sodium, 500 mg |
865 |
412 |
$4K |
| 86922 |
|
50 |
39 |
$4K |
| 92550 |
|
14 |
14 |
$4K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
19 |
17 |
$4K |
| 73620 |
|
1,244 |
1,135 |
$4K |
| 51797 |
|
889 |
876 |
$4K |
| 86593 |
|
1,290 |
1,261 |
$4K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
11,426 |
7,446 |
$4K |
| 99407 |
|
314 |
283 |
$4K |
| 86618 |
|
350 |
337 |
$4K |
| J9070 |
Cyclophosphamide, 100 mg |
89 |
55 |
$4K |
| 81243 |
|
77 |
77 |
$4K |
| 77417 |
|
607 |
275 |
$4K |
| 90716 |
|
4,380 |
4,324 |
$4K |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
104 |
53 |
$4K |
| 94660 |
|
16 |
12 |
$4K |
| 87272 |
|
408 |
401 |
$3K |
| 76098 |
|
309 |
289 |
$3K |
| 0111A |
|
211 |
211 |
$3K |
| D0150 |
Comprehensive oral evaluation - new or established patient |
82 |
77 |
$3K |
| 30140 |
|
14 |
14 |
$3K |
| 97163 |
|
54 |
54 |
$3K |
| 87046 |
|
449 |
432 |
$3K |
| 83090 |
|
317 |
307 |
$3K |
| 72128 |
|
150 |
142 |
$3K |
| 87045 |
|
448 |
431 |
$3K |
| 72195 |
|
12 |
12 |
$3K |
| 78264 |
|
12 |
12 |
$3K |
| 92585 |
|
12 |
12 |
$3K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
13,382 |
11,188 |
$3K |
| 90713 |
|
744 |
722 |
$3K |
| 36475 |
|
13 |
13 |
$3K |
| 80171 |
|
181 |
159 |
$3K |
| A4550 |
Surgical trays |
3,317 |
3,169 |
$3K |
| 82075 |
|
452 |
391 |
$3K |
| 59200 |
|
13 |
12 |
$3K |
| 0112A |
|
76 |
76 |
$3K |
| 86777 |
|
284 |
269 |
$3K |
| 99404 |
|
30 |
30 |
$3K |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
1,035 |
757 |
$3K |
| A9555 |
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
250 |
239 |
$3K |
| 36591 |
|
284 |
257 |
$3K |
| 80299 |
|
347 |
325 |
$3K |
| 84207 |
|
144 |
144 |
$3K |
| J1453 |
Injection, fosaprepitant, 1 mg |
120 |
64 |
$3K |
| 74181 |
|
17 |
16 |
$3K |
| 87341 |
|
369 |
367 |
$3K |
| 88311 |
|
1,216 |
1,145 |
$3K |
| 76519 |
|
83 |
80 |
$3K |
| 82390 |
|
431 |
421 |
$3K |
| 51700 |
|
59 |
52 |
$3K |
| 51702 |
|
265 |
222 |
$3K |
| 82731 |
|
44 |
41 |
$3K |
| 0073A |
|
55 |
55 |
$3K |
| 88360 |
|
363 |
334 |
$3K |
| ATP13 |
|
367 |
347 |
$2K |
| 99497 |
|
119 |
107 |
$2K |
| J3371 |
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg |
1,855 |
955 |
$2K |
| 83937 |
|
206 |
198 |
$2K |
| 11057 |
|
13 |
13 |
$2K |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
614 |
552 |
$2K |
| J1836 |
Injection, metronidazole, 10 mg |
1,181 |
796 |
$2K |
| 86778 |
|
223 |
214 |
$2K |
| 83020 |
|
217 |
215 |
$2K |
| 80185 |
|
393 |
306 |
$2K |
| 86341 |
|
159 |
143 |
$2K |
| 87209 |
|
167 |
164 |
$2K |
| 84478 |
|
1,340 |
1,258 |
$2K |
| J1956 |
Injection, levofloxacin, 250 mg |
29 |
24 |
$2K |
| 87269 |
|
232 |
228 |
$2K |
| 97750 |
|
77 |
71 |
$2K |
| 81050 |
|
1,397 |
1,306 |
$2K |
| 84075 |
|
2,894 |
2,740 |
$2K |
| 82955 |
|
244 |
242 |
$2K |
| 86231 |
|
189 |
187 |
$2K |
| 85060 |
|
554 |
531 |
$2K |
| 87497 |
|
194 |
154 |
$2K |
| 64642 |
|
12 |
12 |
$2K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
656 |
635 |
$2K |
| 80175 |
|
229 |
211 |
$2K |
| 90887 |
|
220 |
206 |
$2K |
| 69209 |
|
63 |
63 |
$2K |
| 86769 |
|
39 |
38 |
$2K |
| G2212 |
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) |
432 |
422 |
$2K |
| 80178 |
|
410 |
368 |
$2K |
| 93797 |
|
35 |
13 |
$2K |
| 90675 |
|
27 |
14 |
$2K |
| 76376 |
|
2,688 |
2,647 |
$2K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
2,775 |
1,010 |
$2K |
| 19301 |
|
14 |
12 |
$2K |
| 86036 |
|
549 |
528 |
$2K |
| 86015 |
|
348 |
346 |
$2K |
| 99152 |
|
702 |
649 |
$2K |
| 92593 |
|
24 |
24 |
$1K |
| J9267 |
Injection, paclitaxel, 1 mg |
1,061 |
446 |
$1K |
| J1940 |
Injection, furosemide, up to 20 mg |
3,933 |
2,443 |
$1K |
| 87350 |
|
207 |
200 |
$1K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
552 |
338 |
$1K |
| 90678 |
|
205 |
205 |
$1K |
| 96900 |
|
91 |
12 |
$1K |
| 0164A |
|
30 |
30 |
$1K |
| 31237 |
|
29 |
25 |
$1K |
| 93284 |
|
82 |
77 |
$1K |
| 0173A |
|
39 |
39 |
$1K |
| 82465 |
|
859 |
818 |
$1K |
| 88312 |
|
402 |
385 |
$1K |
| 99406 |
|
109 |
102 |
$1K |
| 57160 |
|
24 |
24 |
$1K |
| 71101 |
|
70 |
67 |
$1K |
| 92285 |
|
227 |
222 |
$1K |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
399 |
340 |
$1K |
| 82166 |
|
37 |
37 |
$1K |
| 92235 |
|
12 |
12 |
$1K |
| A4215 |
Needle, sterile, any size, each |
1,232 |
1,196 |
$1K |
| V5266 |
Battery for use in hearing device |
54 |
53 |
$1K |
| 82523 |
|
211 |
203 |
$1K |
| 76825 |
|
622 |
611 |
$1K |
| 0094A |
|
49 |
49 |
$1K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
174 |
168 |
$1K |
| 84144 |
|
94 |
87 |
$1K |
| 80156 |
|
131 |
124 |
$1K |
| 85240 |
|
68 |
66 |
$1K |
| J9190 |
Injection, fluorouracil, 500 mg |
4,531 |
1,873 |
$980.90 |
| 73000 |
|
67 |
62 |
$979.62 |
| 93320 |
|
1,497 |
1,486 |
$976.46 |
| 87177 |
|
155 |
152 |
$975.59 |
| J3480 |
Injection, potassium chloride, per 2 meq |
5,027 |
3,056 |
$967.45 |
| 94250 |
|
12 |
12 |
$967.02 |
| 83718 |
|
175 |
171 |
$949.24 |
| 86308 |
|
224 |
220 |
$943.62 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
38 |
37 |
$940.38 |
| 83930 |
|
264 |
244 |
$915.80 |
| 87593 |
|
13 |
13 |
$892.50 |
| 99417 |
Prolong home eval add 15m |
1,727 |
1,617 |
$891.12 |
| 95249 |
|
85 |
74 |
$882.00 |
| 86256 |
|
145 |
135 |
$876.48 |
| 0174A |
|
41 |
41 |
$825.66 |
| 85049 |
|
398 |
375 |
$822.18 |
| 76377 |
|
480 |
464 |
$811.97 |
| 90687 |
|
1,678 |
1,638 |
$779.24 |
| ATP19 |
|
80 |
77 |
$764.90 |
| 91306 |
|
9,349 |
9,059 |
$756.40 |
| 36592 |
|
160 |
150 |
$752.81 |
| 84155 |
|
1,262 |
1,185 |
$716.93 |
| 92556 |
|
37 |
37 |
$705.30 |
| 82172 |
|
64 |
56 |
$655.59 |
| 11901 |
|
12 |
12 |
$650.02 |
| 97012 |
|
19 |
12 |
$622.79 |
| 93786 |
|
52 |
50 |
$621.41 |
| 76827 |
|
616 |
608 |
$611.02 |
| 86905 |
|
227 |
216 |
$602.52 |
| 83695 |
|
36 |
36 |
$594.96 |
| 95250 |
|
26 |
26 |
$585.81 |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
40 |
40 |
$583.23 |
| 86317 |
|
92 |
81 |
$567.22 |
| H0033 |
Oral medication administration, direct observation |
794 |
563 |
$565.11 |
| L4360 |
Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
87 |
83 |
$557.20 |
| 88302 |
|
254 |
176 |
$550.15 |
| 85246 |
|
29 |
28 |
$547.36 |
| 85245 |
|
29 |
28 |
$547.36 |
| J9250 |
Methotrexate sodium, 5 mg |
53 |
24 |
$545.66 |
| 96132 |
|
95 |
93 |
$541.68 |
| Q2035 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) |
294 |
293 |
$502.03 |
| 84157 |
|
258 |
233 |
$479.83 |
| 84446 |
|
57 |
55 |
$469.98 |
| 82085 |
|
128 |
122 |
$446.38 |
| 86258 |
|
40 |
39 |
$444.12 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
20 |
19 |
$437.27 |
| 85014 |
|
314 |
295 |
$428.35 |
| 83935 |
|
142 |
138 |
$419.60 |
| 85055 |
|
15 |
13 |
$409.76 |
| 95885 |
|
14 |
14 |
$388.17 |
| A9561 |
Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries |
216 |
209 |
$386.98 |
| 73660 |
|
39 |
38 |
$380.91 |
| 89320 |
|
126 |
117 |
$380.88 |
| 73522 |
|
14 |
13 |
$380.42 |
| 82164 |
|
61 |
55 |
$376.50 |
| 91307 |
|
3,639 |
3,350 |
$361.20 |
| 91319 |
|
12 |
12 |
$351.12 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
123 |
120 |
$346.11 |
| 93226 |
|
49 |
41 |
$339.96 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
401 |
339 |
$338.02 |
| 93922 |
|
13 |
13 |
$337.50 |
| 73521 |
|
12 |
12 |
$334.63 |
| 97168 |
|
14 |
13 |
$329.16 |
| L1902 |
Ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf |
12 |
12 |
$322.79 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
1,379 |
1,168 |
$321.94 |
| 95874 |
|
27 |
25 |
$314.45 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
2,847 |
1,757 |
$308.54 |
| 82365 |
|
31 |
28 |
$305.76 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
2,030 |
2,007 |
$295.79 |
| 86381 |
|
26 |
26 |
$291.85 |
| J9999 |
Not otherwise classified, antineoplastic drugs |
1,945 |
1,246 |
$289.20 |
| 71110 |
|
17 |
13 |
$289.13 |
| 96116 |
|
13 |
12 |
$284.42 |
| 82140 |
|
33 |
25 |
$275.63 |
| 82945 |
|
116 |
103 |
$254.10 |
| 86707 |
|
25 |
25 |
$248.65 |
| 90836 |
|
17 |
15 |
$246.60 |
| Q0111 |
Wet mounts, including preparations of vaginal, cervical or skin specimens |
41 |
41 |
$244.45 |
| 96137 |
|
38 |
37 |
$240.00 |
| 95700 |
|
187 |
183 |
$237.64 |
| 86789 |
|
35 |
27 |
$222.60 |
| 86788 |
|
35 |
27 |
$220.80 |
| 91303 |
|
2,575 |
2,376 |
$219.66 |
| 82232 |
|
41 |
39 |
$217.13 |
| 82952 |
|
61 |
61 |
$211.92 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
445 |
339 |
$208.90 |
| 99172 |
|
890 |
888 |
$198.04 |
| 82595 |
|
52 |
50 |
$196.42 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
308 |
125 |
$195.87 |
| A9609 |
Fludeoxyglucose f18 up to 15 millicuries |
591 |
560 |
$195.20 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
38 |
36 |
$185.08 |
| L8000 |
Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type |
947 |
858 |
$184.04 |
| A4300 |
Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access |
26 |
25 |
$183.51 |
| 86382 |
|
12 |
12 |
$178.92 |
| 82542 |
|
13 |
13 |
$167.58 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
229 |
133 |
$167.14 |
| 87185 |
|
38 |
38 |
$162.73 |
| 17003 |
|
13 |
13 |
$162.50 |
| 90749 |
|
13 |
13 |
$162.38 |
| 87420 |
|
13 |
13 |
$159.51 |
| 76001 |
|
78 |
66 |
$157.66 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
101 |
92 |
$152.57 |
| 88363 |
|
16 |
16 |
$142.14 |
| J1953 |
Injection, levetiracetam, 10 mg |
201 |
142 |
$141.36 |
| J1817 |
Insulin for administration through dme (i.e., insulin pump) per 50 units |
2,008 |
890 |
$136.77 |
| J1756 |
Injection, iron sucrose, 1 mg |
64 |
42 |
$135.78 |
| 82340 |
|
60 |
56 |
$132.80 |
| 0171A |
|
31 |
31 |
$129.83 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
118 |
100 |
$121.89 |
| 80329 |
|
1,276 |
1,157 |
$115.50 |
| 87206 |
|
41 |
37 |
$114.00 |
| 96381 |
|
227 |
227 |
$110.88 |
| 80051 |
|
149 |
122 |
$105.17 |
| 82180 |
|
30 |
26 |
$104.64 |
| 91300 |
|
23,082 |
19,499 |
$103.21 |
| J7510 |
Prednisolone oral, per 5 mg |
55 |
52 |
$89.36 |
| 87181 |
|
13 |
12 |
$87.99 |
| 86880 |
|
25 |
24 |
$86.46 |
| 87449 |
|
25 |
24 |
$80.93 |
| 70360 |
|
12 |
12 |
$79.44 |
| J2560 |
Injection, phenobarbital sodium, up to 120 mg |
115 |
86 |
$71.00 |
| G0105 |
Colorectal cancer screening; colonoscopy on individual at high risk |
15 |
15 |
$62.43 |
| 90696 |
|
2,096 |
2,084 |
$62.41 |
| 90633 |
|
5,407 |
5,361 |
$54.25 |
| 85260 |
|
13 |
12 |
$48.99 |
| 86702 |
|
15 |
12 |
$43.56 |
| 81015 |
|
16 |
16 |
$40.35 |
| 99153 |
Mod sedat endo service >5yrs |
771 |
725 |
$37.47 |
| 86701 |
|
15 |
12 |
$36.64 |
| 69200 |
|
12 |
12 |
$35.76 |
| 30901 |
|
13 |
13 |
$34.24 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
3,304 |
2,639 |
$29.38 |
| 90611 |
|
68 |
63 |
$25.80 |
| 87210 |
|
15 |
13 |
$23.33 |
| 99606 |
|
22 |
15 |
$21.50 |
| 91305 |
|
1,241 |
1,209 |
$16.90 |
| 87176 |
|
13 |
13 |
$15.57 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
556 |
495 |
$8.47 |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
17 |
14 |
$7.08 |
| C9113 |
Injection, pantoprazole sodium, per vial |
1,620 |
982 |
$6.82 |
| A6209 |
Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
41 |
41 |
$4.44 |
| 91313 |
|
4,080 |
3,908 |
$4.37 |
| 91312 |
|
3,724 |
3,596 |
$0.01 |
| Q0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg |
192 |
127 |
$0.01 |
| 90700 |
|
3,010 |
2,991 |
$0.00 |
| 90710 |
|
1,939 |
1,927 |
$0.00 |
| G9011 |
Coordinated care fee, risk adjusted maintenance, level 5 |
26,094 |
20,438 |
$0.00 |
| T2024 |
Service assessment/plan of care development, waiver |
6,936 |
4,687 |
$0.00 |
| 90681 |
|
5,734 |
5,712 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
717 |
692 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
324 |
275 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,540 |
1,444 |
$0.00 |
| 96113 |
|
1,637 |
1,591 |
$0.00 |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
197 |
116 |
$0.00 |
| 90648 |
|
2,737 |
2,721 |
$0.00 |
| 90685 |
|
286 |
262 |
$0.00 |
| 90690 |
|
15 |
15 |
$0.00 |
| G9004 |
Coordinated care fee, risk adjusted low, initial |
863 |
654 |
$0.00 |
| T2038 |
Community transition, waiver; per service |
330 |
280 |
$0.00 |
| G0390 |
Trauma response team associated with hospital critical care service |
107 |
97 |
$0.00 |
| 78434 |
|
13 |
13 |
$0.00 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
250 |
237 |
$0.00 |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
18 |
14 |
$0.00 |
| 91311 |
|
322 |
320 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,695 |
1,539 |
$0.00 |
| 91308 |
|
743 |
737 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
369 |
346 |
$0.00 |
| 88344 |
|
12 |
12 |
$0.00 |
| J1450 |
Injection fluconazole, 200 mg |
144 |
116 |
$0.00 |
| G9919 |
Screening performed and positive and provision of recommendations |
143 |
143 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
217 |
170 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
343 |
323 |
$0.00 |
| L1820 |
Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
28 |
27 |
$0.00 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
123 |
94 |
$0.00 |
| J3473 |
Injection, hyaluronidase, recombinant, 1 usp unit |
16 |
16 |
$0.00 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
110 |
81 |
$0.00 |
| 96133 |
|
38 |
38 |
$0.00 |
| 94664 |
|
28 |
28 |
$0.00 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
12 |
12 |
$0.00 |
| 93356 |
|
13 |
13 |
$0.00 |
| 94375 |
|
26 |
26 |
$0.00 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
13 |
12 |
$0.00 |
| Q9961 |
High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml |
12 |
12 |
$0.00 |
| 96136 |
|
24 |
24 |
$0.00 |
| 72202 |
|
16 |
13 |
$0.00 |
| 99221 |
|
20 |
18 |
$0.00 |
| 75565 |
|
12 |
12 |
$0.00 |
| 90380 |
|
38 |
38 |
$0.00 |
| J1631 |
Injection, haloperidol decanoate, per 50 mg |
15 |
13 |
$0.00 |
| 94761 |
|
122 |
114 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
507 |
475 |
$0.00 |
| 80320 |
|
1,627 |
1,484 |
$0.00 |
| 90744 |
|
3,354 |
3,308 |
$0.00 |
| 90680 |
|
413 |
370 |
$0.00 |
| G0506 |
Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) |
1,252 |
1,022 |
$0.00 |
| J8501 |
Aprepitant, oral, 5 mg |
551 |
357 |
$0.00 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
28 |
28 |
$0.00 |
| 91309 |
|
48 |
48 |
$0.00 |
| 90657 |
|
246 |
245 |
$0.00 |
| G9005 |
Coordinated care fee, risk adjusted maintenance |
48,340 |
34,331 |
$0.00 |
| G9007 |
Coordinated care fee, scheduled team conference |
693 |
436 |
$0.00 |
| 73600 |
|
14 |
13 |
$0.00 |
| 90697 |
|
3,522 |
3,501 |
$0.00 |
| 91316 |
|
30 |
30 |
$0.00 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
109 |
104 |
$0.00 |
| 91317 |
|
228 |
220 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
12 |
12 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
45 |
38 |
$0.00 |
| 78320 |
|
46 |
45 |
$0.00 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
49 |
29 |
$0.00 |
| 90619 |
|
58 |
58 |
$0.00 |
| J1921 |
Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg |
14 |
12 |
$0.00 |
| J3590 |
Unclassified biologics |
247 |
185 |
$0.00 |
| 91315 |
|
442 |
441 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
13 |
12 |
$0.00 |
| 90698 |
|
268 |
230 |
$0.00 |
| G0416 |
Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method |
79 |
75 |
$0.00 |
| 99402 |
|
54 |
53 |
$0.00 |
| 73120 |
|
12 |
12 |
$0.00 |
| J3357 |
Ustekinumab, for subcutaneous injection, 1 mg |
13 |
13 |
$0.00 |
| 90381 |
|
161 |
161 |
$0.00 |
| J2020 |
Injection, linezolid, 200 mg |
42 |
26 |
$0.00 |
| 95831 |
|
25 |
25 |
$0.00 |
| J0611 |
Injection, calcium gluconate (wg critical care), per 10 ml |
30 |
24 |
$0.00 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
44 |
38 |
$0.00 |
| Q0221 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg |
60 |
57 |
$0.00 |
| 96380 |
|
22 |
22 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
13 |
12 |
$0.00 |
| C9399 |
Unclassified drugs or biologicals |
21 |
20 |
$0.00 |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
28 |
13 |
$0.00 |
| 54235 |
|
14 |
13 |
$0.00 |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
91 |
89 |
$0.00 |
| 96377 |
|
21 |
12 |
$0.00 |
| 88331 |
|
14 |
13 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
17 |
14 |
$0.00 |
| A9597 |
Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified |
13 |
13 |
$0.00 |